In: Amir Ashraf S, Adnan M, eds
Refrigeration at 2 to 8C slows but does not stop these reactions
Market Drivers : Growth is driven by the rising prevalence of obesity and Type 2 diabetes, the shift toward incretin-based therapies, expanding clinical evidence of weight-loss benefits, and improved patient awareness, supported by physician advocacy and digital health engagement
Your healthcare provider will build a personalized plan just for you
Age alone is not a contraindication, What matters is your overall health, medical history, and proper evaluation before starting therapy
Clinical studies have reported more significant weight loss with tirzepatide compared to semaglutide, making it an excellent alternative for those who arent seeing the desired effects or are experiencing intolerable side effects